Clinical trial
An Open, Single Arm, Multicenter, Exploratory Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type Patients With Metastatic Colorectal Carcinoma as 1st Therapy
NCT04080843 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open, Single Arm, Multicenter, Exploratory Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type Patients With Metastatic Colorectal Carcinoma as 1st Therapy
- Lead sponsor
- Zhejiang University
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 15, 2019
- Completion date
- July 1, 2022
- Enrollment
- 30 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
colonic diseases, colorectal cancer, colorectal neoplasms, digestive system diseases, digestive system neoplasms, gastrointestinal diseases, gastrointestinal neoplasms, intestinal diseases, intestinal neoplasms, neoplasms, neoplasms by site, ras and braf wild-type, rectal diseases